



MEDICO REMEDIES LTD.

A WHO-GMP, ISO 9001-2015 & GOVT. RECOGNISED STAR EXPORT HOUSE

Manufacturers of Pharmaceutical Formulations



CIN : L24230MH1994PLC077187
GSTIN- 27AABCM8349L1ZY

Regd. Office : 1105/1106, Hubtown Solaris, N. S. Phadke Marg, Opp. Teligali, Andheri - East, Mumbai - 400 069. • Tel. : +91-22-2682 1054 / 1055 / 2683 7116
Email : medicoremedies@yahoo.com, medicoremediesindia@yahoo.com • Website : www.medicoremediesindia.com

Date: 25th May, 2019

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

Script Code : 540937

Dear Sir,

Re.: Outcome of the Board Meeting held today

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that at the Meeting of Board of Directors of our Company held today i.e. 25th May, 2019 has, inter alia considered and approved the following:

1. Audited Standalone Financial Results of the Company for the half year ended 31st March, 2019 and Audited Financial Statements for the year ended on 31st March, 2019 along with the Auditor's Report thereon.

We wish to inform you that the Board Meeting commenced today at 1.00 P.M and concluded at 2.00 P.M

Kindly take the same on record and oblige.

Yours faithfully,

For MEDICO REMEDIES LIMITED

H. Mehta

**HARSHIT MEHTA
MANAGING DIRECTOR
DIN: 05144280**

Encl:

1. Audited Financial Results for the half year ended 31st March, 2019 and Audited Financial Statements for the year ended 31st March, 2019 and Auditors Report thereon.
2. Declaration on Unmodified Opinion of the Audited Financial Statements for the year ended 31st March, 2019.

Independent Auditor's Report on Six Monthly Financial Results and Year to Date Results of Medico Remedies Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


To Board of Directors of
Medico Remedies Limited

1. We have audited the six monthly financial results of **Medico Remedies Limited** for the six months and the year to date results for the period ended 31st March 2019, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the half year ended 31st March 2019 are balancing figures between audited figures of full financial year and audited year to date figures upto the half year ended 30th September 2018.
2. This Statement has been prepared on the basis of the audited financial statements, which is the responsibility of the Company's management and have been approved by the Board of Directors of the Company.
3. Our responsibility is to express an opinion on these financial results based on our audit of the financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standards prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India; our audit of the annual standalone financial statements as at and for the year ended March 31, 2019; and relevant requirements of the Regulation and the Circular.
4. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
5. In our opinion and to the best of our information and according to the explanations given to us these six monthly financial results as well as the year to date results:
 - (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
 - (ii) give a true and fair view of the net profit and other financial information for the six months ended and year ended 31st March 2019.

Place: Mumbai

For V. J. SHAH & CO.
Chartered Accountants
Firm's Registration No: 109823W

Date: 25.05.2019


(Chintan V Shah)
Partner
Membership No. 164370



MEDICO REMEDIES LIMITED
CIN: U24230MH1994PLC077187

Statement of Audited Financial Results for the year ended 31st March 2019. (Rs. In Lacs)

Sl No	Particulars	6 months ended 31.03.2019	6 months ended 30.09.2018	6 months ended 31.03.2018	Year ended 31.03.2019	Year ended 31.03.2018
I	Revenue From Operations	5,621.81	4,146.98	3,175.04	9,768.79	6,102.46
II	Other Income	63.00	127.19	42.70	190.19	91.30
III	Total Revenue	5,684.81	4,274.17	3,217.74	9,958.98	6,193.75
IV	Expenses					
(a)	Cost of Material Consumed	4,377.73	3,466.86	2,387.03	7,844.58	4,531.43
(b)	Purchase of Stock-in-Trade	98.43	91.16	40.03	189.59	64.44
(c)	Changes in Inventories of Finished Goods, Work in Progress and Stock in Trade	114.61	-197.08	-167.24	-82.47	-246.37
(d)	Employee Benefits Expenses	160.52	171.94	204.27	332.46	389.45
(e)	Finance Cost	45.60	52.17	56.30	97.77	151.68
(f)	Depreciation and Amortisation Expenses	79.81	71.38	51.75	151.18	100.46
(g)	Other Expenses	658.43	549.92	520.42	1,208.35	1,015.38
V	Total Expenses	5,535.12	4,206.34	3,092.57	9,741.47	6,006.48
VI	Profit before exceptional and extraordinary items and tax	149.68	67.83	125.17	217.51	187.28
VII	Profit before extraordinary items and tax	149.68	67.83	125.17	217.51	187.28
VIII	Extraordinary items					
IX	Profit before tax	149.68	67.83	125.17	217.51	187.28
X	Tax expense					
(a)	Current Tax	36.39	18.32	37.00	54.71	55.00
(b)	Deferred Tax	1.68	4.11	6.17	5.79	10.26
XI	Profit for the period from continuing operations	111.61	45.40	82.00	157.01	122.02
XII	Profit/(loss) from discontinuing operations					
XIII	Tax expense of discontinuing operations					
XIV	Profit/(loss) from Discontinuing operations (after tax)					
XV	Profit for the period	111.61	45.40	82.00	157.01	122.02
XVI	Earnings Per Equity Share					
(a)	Basic	2.69	1.09	4.74	3.78	3.65
(b)	Diluted	2.69	1.09	4.74	3.78	3.65
	See accompanying note to Financial Results					

Ahmedkta



MEDICO REMEDIES LIMITED
CIN: U24230MH1994PLC077187
Balance Sheet As At 31st March 2019 (Rs. In Lacs)

Sr.	Particulars	As at 31.03.2019	As at 30.09.2018	As at 31.03.2018
		Audited	Audited	Audited
I	EQUITY AND LIABILITIES			
1	Shareholders' Funds			
(a)	Share Capital	414.92	414.92	414.92
(b)	Reserves and Surplus	2,408.66	2,297.05	2,251.64
(c)	Money received against share warrants	-	-	-
	Sub-total - Shareholders' funds	2,823.58	2,711.97	2,666.56
2	Share application money pending allotment	-	-	-
	Sub-total - Share application money pending allotment	-	-	-
3	Non-Current Liabilities			
(a)	Long-Term Borrowings	237.47	187.28	218.99
(b)	Deferred Tax Liabilities (Net)	17.62	15.93	11.83
(c)	Other Long Term Liabilities	7.50	15.00	15.00
(d)	Long Term Provisions	-	13.93	8.93
	Sub-total - Non-current liabilities	262.58	232.14	254.75
4	Current Liabilities			
(a)	Short-Term Borrowings	1,026.95	967.36	968.79
(b)	Trade Payables		-	-
	i. Total outstanding dues of micro enterprises and small enterprises	6.21	3.73	4.36
	ii. Total outstanding dues of creditors other than micro enterprises and small enterprises	3,245.85	2,182.00	1,747.39
(c)	Other Current Liabilities	265.76	186.17	296.67
(d)	Short Term Provisions	-	-	-
	Sub-total - Current liabilities	4,544.77	3,339.26	3,017.21
	TOTAL - EQUITY AND LIABILITIES	7,630.93	6,283.37	5,938.52
B	ASSETS			
1	Non Current Assets			
(a)	Fixed Assets			
	i. Tangible Assets	1,226.82	1,097.67	663.07
	ii. Intangible Assets	-	-	-
	iii. Capital Work-in-Progress	89.53	-	436.93
	iv. Intangible Assets under development	-	-	-
(b)	Non-Current Investments	15.00	23.69	23.78
(c)	Deferred tax assets (net)	-	-	-
(d)	Long-Term Loans and Advances	376.61	351.88	245.70
(e)	Other non-current assets	4.58	-	-
	Sub-total - Non-current assets	1,712.54	1,473.24	1,369.47
2)	Current Assets			
(a)	Current Investments	-	-	-
(b)	Inventories	1,607.07	1,494.59	1,491.05
(c)	Trade Receivables	2,907.32	1,940.22	1,700.86
(d)	Cash & Cash Equivalents	61.45	15.41	81.40
(e)	Bank Balance other than cash and cash equivalents	-	-	-
(f)	Short-Term Loans and Advances	1,272.57	1,183.20	1,234.02
(g)	Other Current Assets	69.99	176.72	61.71
	Sub-total - Current assets	5,918.39	4,810.13	4,569.05
	TOTAL - ASSETS	7,630.93	6,283.37	5,938.52

Hhmagter



MEDICO REMEDIES LIMITED
CIN: U24230MH1994PLC077187

Notes to Financial Results

1. The above audited standalone financial results of the company were reviewed and recommended by the audit committee on 25th May, 2019 and subsequently approved by the Board of Directors at its meeting held on the 25th May, 2019. The review report has been filed with stock exchange and is available on the Company's website. (www.medicoremedies.com)
2. The figures for the half year ended 31st March 2019 are balancing figures between audited figures of full financial year and audited year to date figures upto the half year ended 30th September 2018.
3. The standalone financial results for the 6 months ended 31st March, 2019 have been subjected to Limited Review by statutory auditors of the company and the statutory auditor has issued unqualified report on Audited Financial Results.
4. There are no separate reportable segments in terms of Accounting Standard – 17 “Segment Information” (AS-17).
5. There are no Investor complaints pending as on 31st March 2019.
6. Previous periods' figures have been regrouped / reclassified where required to make them compatible with the figures of current periods.





MEDICO REMEDIES LTD.

A WHO-GMP, ISO 9001-2015 & GOVT. RECOGNISED STAR EXPORT HOUSE

Manufacturers of Pharmaceutical Formulations



CIN - L24230MH1994PLC077187
GSTIN- 27AABCM8349L12Y

Regd. Office : 1105/1106, Hubtown Solaris, N. S. Phadke Marg, Opp. Teligali, Andheri - East, Mumbai - 400 069. • Tel.: +91-22-2682 1054 / 1055 / 2683 7116
Email : medicoremedies@yahoo.com, medicoremediesindia@yahoo.com • Website : www.medicoremediesindia.com

25th May, 2019

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Script Code: 540937

Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir,

I, Haresh Mehta, Chief Financial Officer of Medico Remedies Limited (CIN: L24230MH1994PLC077187) having its registered office at 1105/1106, 11th Floor, Hubtown Solaris, Opp. Telli Galli, N S Phadke Marg, Andheri East, Mumbai-400069 hereby declare that the Statutory Auditors M/s. V J Shah & Co, Chartered Accountants (FRN: 109823W) have issued an Audit Report with Unmodified Opinion on the Audited Financial Statements of the Company for the financial year ended on March 31, 2019.

This disclosure is given in compliance to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulation 2006 vide Notification no SEBI/LAD/NRO/GN/2016-17/001 dated May 25, 2016 and Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take the declaration on your records.

Thanking you,

Yours faithfully,
For MEDICO REMEDIES LIMITED

HARESH MEHTA
CHIEF FINANCIAL OFFICER